%0 Case Reports
%T Effectiveness of Highly Purified Cannabidiol in Refractory and Super-Refractory Status Epilepticus: A Case Series.
%A Di Mauro G
%A Vietri G
%A Quaranta L
%A Placidi F
%A Izzi F
%A Castelli A
%A Pagano A
%A Leonardis F
%A De Angelis V
%A Bianco C
%A Celeste MG
%A Mercuri NB
%A Liguori C
%J CNS Neurol Disord Drug Targets
%V 0
%N 0
%D 2024 Jun 21
%M 38910424
%F 2.824
%R 10.2174/0118715273304077240603115521
%X <B>BACKGROUND: </B>Refractory and super-refractory status epilepticus are medical emergencies that must be promptly treated in consideration of their high mortality and morbidity rate. Nevertheless, the available evidence of effective treatment of these conditions is scarce. Among novel antiseizure medications (ASMs), highly purified cannabidiol (hpCBD) has shown noteworthy efficacy in reducing seizures in Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC).<BR><B>METHODS: </B>Here, we present two cases of effective use of hpCBD in both refractory and super- refractory status epilepticus. The administration of the nasogastric tube permitted the resolution of status epilepticus without adverse events. At 6-month follow-up, both patients were on hpCBD treatment, which continued to be efficacious for treating seizures.<BR><B>CONCLUSIONS: </B>According to our experience, hpCBD should be taken into consideration as an add-on therapy of RSE and SRSE while also considering the possibility of maintaining this treatment during the follow-up of patients. However, more studies and real-world experiences are needed to better understand its effectiveness in this setting and the interaction with other ASMs.